KANT
Price
$0.34
Change
+$0.05 (+17.24%)
Updated
Jun 27 closing price
Capitalization
4.55M
SLNO
Price
$87.45
Change
+$1.43 (+1.66%)
Updated
Jul 23 closing price
Capitalization
4.61B
13 days until earnings call
Interact to see
Advertisement

KANT vs SLNO

Header iconKANT vs SLNO Comparison
Open Charts KANT vs SLNOBanner chart's image
Kineta
Price$0.34
Change+$0.05 (+17.24%)
Volume$360
Capitalization4.55M
Soleno Therapeutics
Price$87.45
Change+$1.43 (+1.66%)
Volume$638.03K
Capitalization4.61B
KANT vs SLNO Comparison Chart in %
Loading...
KANT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KANT vs. SLNO commentary
Jul 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KANT is a Buy and SLNO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 24, 2025
Stock price -- (KANT: $0.34 vs. SLNO: $87.45)
Brand notoriety: KANT and SLNO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KANT: 3% vs. SLNO: 59%
Market capitalization -- KANT: $4.55M vs. SLNO: $4.61B
KANT [@Biotechnology] is valued at $4.55M. SLNO’s [@Biotechnology] market capitalization is $4.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $295.06B to $0. The average market capitalization across the [@Biotechnology] industry is $2.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KANT’s FA Score shows that 1 FA rating(s) are green whileSLNO’s FA Score has 0 green FA rating(s).

  • KANT’s FA Score: 1 green, 4 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, both KANT and SLNO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KANT’s TA Score shows that 4 TA indicator(s) are bullish while SLNO’s TA Score has 3 bullish TA indicator(s).

  • KANT’s TA Score: 4 bullish, 3 bearish.
  • SLNO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, KANT is a better buy in the short-term than SLNO.

Price Growth

KANT (@Biotechnology) experienced а 0.00% price change this week, while SLNO (@Biotechnology) price change was +2.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.15%. For the same industry, the average monthly price growth was +22.17%, and the average quarterly price growth was +31.45%.

Reported Earning Dates

KANT is expected to report earnings on May 15, 2025.

SLNO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+8.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($4.61B) has a higher market cap than KANT($4.55M). SLNO YTD gains are higher at: 94.549 vs. KANT (-4.024). KANT has higher annual earnings (EBITDA): -20.45M vs. SLNO (-194.63M). SLNO has more cash in the bank: 290M vs. KANT (900K). KANT has less debt than SLNO: KANT (710K) vs SLNO (52.8M). KANT (0) and SLNO (0) have equivalent revenues.
KANTSLNOKANT / SLNO
Capitalization4.55M4.61B0%
EBITDA-20.45M-194.63M11%
Gain YTD-4.02494.549-4%
P/E RatioN/AN/A-
Revenue00-
Total Cash900K290M0%
Total Debt710K52.8M1%
FUNDAMENTALS RATINGS
KANT vs SLNO: Fundamental Ratings
KANT
SLNO
OUTLOOK RATING
1..100
2113
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4638
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KANT's Valuation (25) in the null industry is significantly better than the same rating for SLNO (100) in the Medical Specialties industry. This means that KANT’s stock grew significantly faster than SLNO’s over the last 12 months.

SLNO's Profit vs Risk Rating (36) in the Medical Specialties industry is somewhat better than the same rating for KANT (100) in the null industry. This means that SLNO’s stock grew somewhat faster than KANT’s over the last 12 months.

SLNO's SMR Rating (98) in the Medical Specialties industry is in the same range as KANT (100) in the null industry. This means that SLNO’s stock grew similarly to KANT’s over the last 12 months.

SLNO's Price Growth Rating (38) in the Medical Specialties industry is in the same range as KANT (46) in the null industry. This means that SLNO’s stock grew similarly to KANT’s over the last 12 months.

SLNO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as KANT (100) in the null industry. This means that SLNO’s stock grew similarly to KANT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KANTSLNO
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
87%
Declines
ODDS (%)
N/A
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KANT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA332.564.07
+1.24%
Tesla
SPY634.215.35
+0.85%
SPDR® S&P 500® ETF
AAPL214.15-0.25
-0.12%
Apple
BTC.X118754.960000-1240.453100
-1.03%
Bitcoin cryptocurrency
GME23.96-0.30
-1.24%
GameStop Corp

KANT and

Correlation & Price change

A.I.dvisor indicates that over the last year, KANT has been loosely correlated with MDGL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if KANT jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KANT
1D Price
Change %
KANT100%
N/A
MDGL - KANT
62%
Loosely correlated
-2.12%
SLNO - KANT
45%
Loosely correlated
+0.55%
VKTX - KANT
35%
Loosely correlated
+4.05%
CELC - KANT
34%
Loosely correlated
+0.79%
MDWD - KANT
29%
Poorly correlated
+2.49%
More

SLNO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with BRNS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNO
1D Price
Change %
SLNO100%
+0.55%
BRNS - SLNO
56%
Loosely correlated
-3.05%
KANT - SLNO
45%
Loosely correlated
N/A
SYRE - SLNO
43%
Loosely correlated
+8.00%
NKTX - SLNO
43%
Loosely correlated
+7.21%
CRNX - SLNO
40%
Loosely correlated
+1.67%
More